Roughly 80% of TTP is activated by deficient action of ADAMTS13. ADAMTS13 deficiency could be constitutive, because of biallelic ADAMTS13 pathogenic variants; or obtained, because of an inhibitory antibody. Analysis of ADAMTS13 action is carried out using tests based upon the potential from the protease to cleave conventional VWF multimers in vitro